THE ROLE OF BOARD MEMBERS
-
Board members are entrepreneurial executives with extensive experience in asset management, startups/SMEs and global corporations
-
Board controls investment, budget, nomination, compensation, audit, and guarantees alignment of interests
-
Board is regulated by an organization charter
-
Board operates its own internal processes and procedures based on EVCA professional standards
THE ROLE OF BOARD MEMBERS
-
Board members are entrepreneurial executives with extensive experience in asset management, startups/SMEs and global corporations
-
Board controls investment, budget, nomination, compensation, audit, and guarantees alignment of interests
-
Board is regulated by an organization charter
-
Board operates its own internal processes and procedures based on EVCA professional standards
Search
TELIX: NDA Clinical Briefing Package Submitted to the US FDA
Melbourne (Australia) – 27th December 2019. Telix Pharmaceuticals Limited (ASX: TLX), is pleased to announce that it has submitted a...
Telix Pharmaceuticals and GE Healthcare : Maximising 68Ga Supply for Prostate Cancer Imaging
Melbourne (Australia) – 14 October 2019. Telix Pharmaceuticals Limited (ASX:TLX, “Telix”, the “Company”) a clinical-stage...
TELIX: FDA Pre-NDA Meeting Outcomes : TLX591-CDx (illumet ™)
TLX591-CDx (68Ga-PSMA) for the imaging of prostate cancer with positron emission tomography (PET).
Telix Pharmaceuticals Reports Positive Consultation for European Approval of Prostate Imaging Agent
Program relevance: TLX591-CDx (68Ga-PSMA-11) for the imaging of metastatic prostate cancer with positron emission tomography (PET)...
Telix Pharmaceuticals and Emory Winship Cancer Institute to Collaborate on Clinical Trial
Program relevance: TLX591-CDx (68Ga-PSMA) for the imaging of prostate cancer with positron emission tomography (PET). Branded as...
TELIX: Prostate Imaging Program (illumetTM) : Commercial and Regulatory Update
TLX591-CDx (68Ga-PSMA) for the imaging of prostate cancer with positron emission tomography (PET). Branded as illumetTM in the US market.
TELIX: Fractionated Prostate Cancer Therapy Data Published, Significant Treatment Benefit
Date: 26th April, 2019 Program relevance: TLX591 (Prostate Therapy), TLX591-CDx (Prostate Imaging) Synopsis: The development of TLX591 is...
TELIX: Strategy Update – Acceleration of Prostate Cancer Therapy Program
Program relevance: TLX591 Synopsis: In conjunction with the completion of the acquisition of Atlab Pharma SAS (ASX release: 11/09/18)...